Small macrocyclic kinase inhibitors
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
41
NCT07040436
Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1
Phase: Phase 1/2
Role: Lead Sponsor
Start: Sep 30, 2025
Completion: Dec 31, 2027
Loading map...